KFF polling finds low awareness of TrumpRx and persistent GLP-1 cost concerns

Only about a third of people who take prescription drugs — 35 percent — said they had heard of TrumpRx, the federal discount drug platform that launched in early 2026, according to KFF polling fielded Feb. 24 to Mar. 2, 2026 ^[1]. The same KFF work found that 59 percent of adults doubt current policies will meaningfully lower drug costs ^[1].

KFF, a health policy research organization, also reported that 72 percent of adults believe the government is not doing enough about drug pricing, a view that runs across party lines ^[1]. Its data note on prescription drug prices says at least two-thirds of Democrats, independents and Republicans say there is not enough regulation of drug prices, and that most adults support policies such as allowing Medicare to negotiate prices and limiting annual price increases to inflation, both provisions of the 2022 Inflation Reduction Act ^[2].

Cost pressure shows up in what people report doing. Sixty-six percent of Americans taking medications said they have cost concerns, and 43 percent said they had adjusted their medication use because of cost, an effect that fell hardest on lower-income households ^[1]. KFF's data note puts the share of adults worried about affording their prescriptions at about six in ten — the highest since KFF began asking in 2018 — with four in ten reporting cost-saving steps such as skipping doses or not filling prescriptions ^[2]. The two cost figures come from different KFF items, one focused on adults taking medications ^[1] and one on adults overall ^[2].

About one in five adults say they have ever taken a GLP-1 medication, and most users, including those with insurance, say the drugs are difficult to afford ^[2]. One KFF summary puts GLP-1 use at nearly 18 percent of adults and notes that TrumpRx lists many major GLP-1 medications but that few users report using the platform to compare prices or make purchases ^[1].

Confidence in the policies divides by party. Republican respondents tended to show more confidence that the administration's drug pricing approach would lower costs, while Democrats and independents were less optimistic, and Medicare beneficiaries were split, according to the same reporting ^[1]. In earlier KFF polling cited in the data note, 82 percent of adults called the cost of prescription drugs unreasonable, and 83 percent said profits made by drug companies are a major factor in those prices ^[2].

Why it matters for patients

Most adults in the U.S. take at least one prescription drug: 66 percent say they currently take one, and 31 percent take four or more ^[2]. KFF polling cited in its data note found that 37 percent of people taking four or more medications report difficulty affording them, compared with 18 percent of those taking three or fewer ^[2].

GLP-1 drugs are generally taken for long periods, and users report affordability problems even when they have insurance ^[2]. A discount platform that most potential users have not heard of may not change those calculations: 35 percent awareness among prescription drug users means most people deciding about or taking a GLP-1 have not reported hearing about TrumpRx ^[1]. The KFF findings do not compare TrumpRx prices with insurance copays or with other discount programs, and whether the platform offers lower prices for any specific GLP-1 has not been reported in these results ^[1][2].

What happens next

KFF says it will keep monitoring the public's experiences with GLP-1 medications as use, regulation and new formulations, including oral versions, continue to change ^[2]. A date for that update has not been disclosed ^[2].